Skip to main content

Table 4 Diagnostics (A), therapeutical interventions (B) and clinical outcomes (C) of WNV-infected patients

From: Identifying risks for severity of neurological symptoms in Hungarian West Nile virus patients

(A) Diagnostics: WNV Laboratory testing, n (%)
 Cerebrospinal fluid yes 48 (72.7)
no 8 (12.1)
data unavailable 10 (15.2)
 Serology serum and CSF positive (IgG, A, M) 62 (93.9)
serum positive (IgG, M) 3 (4.5)
serum positive (IgG: inconclusive, IgA: borderline, IgM: positive) 1 (1.5)
 PCR positive 17 (5.8)
negative 37 (55.9)
data unavailable 10 (15.2)
inconclusive 2 (3.0)
 Lineage lineage 2 17 (25.8)
unknown (due to PCR-negative or inconclusive results) 39 (59,0)
not applicable 10 (15.2)
Other (relevant) Diagnostic procedures, n (%)
 Imaging Confirmed alteration with CT 10 (15.2)
Confirmed alteration with MRI 7 (10.6)
Confirmed alteration with both CT and MRI 19 (28.8)
none 24 (36.4)
data unavailable 6 (9.1)
(B) Therapy, n (%)
 Antibiotic/Antiviral treatment Antibiotic treatment 12 (18.2)
Antiviral treatment 1 (1.5)
Antibiotic+ Antiviral treatment 32 (48.5)
none 21 (31.8)
 Pain medication Minor analgesics 39 (59.1)
Major analgesics 3 (4.5)
Both minor and major analgesics 1 (1.5)
none 21 (31.8)
data unavailable 2 (3.0)
 Other relevant medication Steroid only 3 (4.55)
Mannitol only 9 (13.64)
Steroid + Mannitol 13 (19.70)
Antiepileptics only 3 (4.55)
Steroid + Mannitol + Sedative 5 (7.58)
Steroid + Mannitol + medication for Dizziness 1 (1.52)
Steroid + Mannitol + Sedative + Antiepileptics 1 (1.52)
none 28 (42.42)
 Intensive Care   9 (13.6)
(C) Clinical outcome, n (%)
 Complications
(respiratory failure, hearing loss, seizures, pneumonia polyneuropathy)
  7 (10.6)
 Death   5 (7.6)
 Length of hospital stay (days) average 10.6
median 9.0